Journal of Clinical Densitometry
Volume 12, Issue 1 , Pages 63-70 , January 2009

Active Comparator Trial of Teriparatide vs Alendronate for Treating Glucocorticoid-Induced Osteoporosis: Results From the Hispanic and Non-Hispanic Cohorts

  • Benito R. Losada

      Affiliations

    • Hospital Universitario de Caracas, Venezuela
    • Corresponding Author InformationAddress correspondence to: Benito R. Losada, MD, Hospital Universitario de Caracas, Ciudad Universitaria, Los Chaguaramos, Caracas, D.F., 1040, Venezuela.
    • ,
  • Jose R. Zanchetta

      Affiliations

    • Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina
    • ,
  • Cristiano Zerbini

      Affiliations

    • Serviço de Reumatologia - Hospital Heliópolis, São Paulo, Brasil
    • ,
  • Jose F. Molina

      Affiliations

    • Unidad de Osteoporosis, Clínica del Prado, Medellín, Colombia
    • ,
  • Pilar De la Peña

      Affiliations

    • Médica Monraz, Guadalajara, México
    • ,
  • Charlie C. Liu

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    • ,
  • Rachel B. Smith

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    • ,
  • Antonio J. Nino

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    • ,
  • Kelly Krohn

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    • ,
  • Margaret R. Warner

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

Received 26 June 2008 ,Revised 7 October 2008 ,Accepted 8 October 2008.

References 

  1. van Staa TP, Leufkens HGM, Abenheim L, et al. Use of oral corticosteroids in the United Kingdom. Q J Med. 2000;93:105–111
  2. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32:135–157
  3. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–282
  4. American College of Rheumatology . Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44(7):1496–1503
  5. Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int. 2006;17:8–19
  6. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441
  7. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9–17
  8. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995;136:3632–3638
  9. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104(4):439–446
  10. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916
  11. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–1936
  12. Broussard D, Magnus JH. Risk assessment and screening for low bone mineral density in a multi-ethnic population of women and men: does one approach fit all?. Osteoporos Int. 2004;15:349–360
  13. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–1768
  14. Jackson KA, Savaiano DA. Lactose maldigestion, calcium intake and osteoporosis in African- Asian- and Hispanic-Americans. J Am Coll Nutr. 2001;20:198S–207S
  15. Barrett-Conner E, Siris ES, Miller PD, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20:185–194
  16. Siris ES, Miller PD, Barrett-Conner E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA. 2001;286:2815–2822
  17. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194:S3–S11
  18. Pothiwala B, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health. 2006;15:709–719
  19. Araujo AB, Travison TG, Harris SS, Holick MF, Turner AK, McKinlay JB. Race/ethnic differences in bone mineral density. Osteoporos Int. 2007;18:943–953
  20. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–2039
  21. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res. 1996;11:984–996
  22. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443
  23. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762–1768
  24. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double blind, placebo controlled extension trial. Arthritis Rheum. 2001;44(1):202–211
  25. Taaffe DR, Villa ML, Holloway L, Marcus R. Bone mineral density in older non-Hispanic Caucasian and Mexican-American women: relationship to lean and fat mass. Ann Human Biol. 2000;27(4):331–344
  26. Tracy JK, Meyer WA, Grigoryan M, et al. Racial differences in the prevalence of vertebral fractures in older men: the Baltimore Men's Osteoporosis Study. Osteoporos Int. 2006;17:99–104
  27. Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int. 2008;[Epub ahead of print]
  28. Morales-Torres J, Gutierrez-Urena S. The burden of osteoporosis in Latin America. Osteoporos Int. 2004;15:625–632
  29. Deleze M, Cons-Molina F, Villa AR, et al. Geographic differences in bone mineral density of Mexican women. Osteoporos Int. 2000;11:562–569
  30. Lauderdale DS, Jacobsen SJ, Furner SE, Levy PS, Brody JA, Goldberg J. Hip fracture incidence among elderly Hispanics. Am J Public Health. 1998;88:1245–1247

PII: S1094-6950(08)00476-9

doi: 10.1016/j.jocd.2008.10.002

Journal of Clinical Densitometry
Volume 12, Issue 1 , Pages 63-70 , January 2009

Article Tools

* Image Usage & Resolution